Edition:
United Kingdom

Regeneron Pharmaceuticals Inc (REGN.OQ)

REGN.OQ on NASDAQ Stock Exchange Global Select Market

323.97USD
26 Apr 2018
Change (% chg)

$7.80 (+2.47%)
Prev Close
$316.17
Open
$318.08
Day's High
$327.05
Day's Low
$316.24
Volume
295,101
Avg. Vol
317,868
52-wk High
$543.50
52-wk Low
$310.53

Chart for

About

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have... (more)

Overall

Beta: 1.44
Market Cap(Mil.): $33,601.40
Shares Outstanding(Mil.): 107.70
Dividend: --
Yield (%): --

Financials

  REGN.OQ Industry Sector
P/E (TTM): 24.07 173.69 32.21
EPS (TTM): 13.14 -- --
ROI: 22.82 -0.70 13.05
ROE: 28.79 -2.69 14.90

BRIEF-Regeneron Pharma CEO's 2017 Compensation Was $26.5 Million

* REGENERON PHARMACEUTICALS INC SAYS PRESIDENT AND CEO LEONARD S. SCHLEIFER'S 2017 TOTAL COMPENSATION WAS $26.5 MILLION VERSUS $28.3 MILLION IN 2016 – SEC FILING

23 Apr 2018

European Medicines Agency to review Sanofi-Regeneron's Dupixent, Cemiplimab

PARIS The European Medicines Agency (EMA) will review the Dupixent (dupilumab) and Cemiplimab products being developed by drugmakers Sanofi and Regeneron, the companies said on Tuesday.

03 Apr 2018

European Medicines Agency to review Sanofi-Regeneron's Dupixent, Cemiplimab

PARIS, April 3 The European Medicines Agency (EMA) will review the Dupixent (dupilumab) and Cemiplimab products being developed by drugmakers Sanofi and Regeneron, the companies said on Tuesday.

03 Apr 2018

BRIEF-‍EMA To Review Dupixent As Potential Treatment For Inadequately Controlled Moderate-To Severe Asthma​

* ‍EMA TO REVIEW DUPIXENT® (DUPILUMAB) AS POTENTIAL TREATMENT FOR INADEQUATELY CONTROLLED MODERATE-TO-SEVERE ASTHMA​

03 Apr 2018

BRIEF-Regeneron, Alnylam Pharmaceuticals Announce Collaboration To Discover New Treatments For Nonalcoholic Steatohepatitis

* REGENERON AND ALNYLAM PHARMACEUTICALS ANNOUNCE COLLABORATION TO DISCOVER NEW TREATMENTS FOR NONALCOHOLIC STEATOHEPATITIS (NASH)

21 Mar 2018

BRIEF-Novartis files patent infringement against Regeneron over latter's manufacture of Eylea, Zaltrap

March 19 Novartis files patent infringement lawsuit against regeneron over latter's manufacturing of eylea, zaltrap -- court filing Novartis alleges that eylea, zaltrap incorporate technology covered by one or more claims of a patent it holds Novartis says the patent in question dates from 1997 and is called 'vector for expression of a polypeptide in a mammalian cell' Novartis seeks compensatory and triple damages for renegeron's alleged willful patent infringement, in a lawsuit file

19 Mar 2018

BRIEF-Eylea (Aflibercept) Injection Demonstrates Positive Topline Results In Phase 3 Non-Proliferative Diabetic Retinopathy Trial

* EYLEA® (AFLIBERCEPT) INJECTION DEMONSTRATES POSITIVE TOPLINE RESULTS IN PHASE 3 NON-PROLIFERATIVE DIABETIC RETINOPATHY TRIAL

19 Mar 2018

Regeneron/Sanofi heart drug succeeds in major trial; Will insurers pay?

A potent, expensive cholesterol drug sold by Regeneron Pharmaceuticals and Sanofi significantly reduced major adverse heart events in a huge study presented on Saturday but it remains to be seen whether the new data will prompt insurers to pay for increased use of the medicine.

10 Mar 2018

Regeneron/Sanofi offer new Praluent pricing to break reimbursement logjam

Regeneron Pharmaceuticals Inc and Sanofi SA said on Saturday they would be willing to charge less for their potent cholesterol drug, Praluent, if insurers agree to lessen onerous access barriers for high-risk patients.

10 Mar 2018

UPDATE 1-Regeneron/Sanofi offer new Praluent pricing to break reimbursement logjam

March 10 Regeneron Pharmaceuticals Inc and Sanofi SA said on Saturday they would be willing to charge less for their potent cholesterol drug, Praluent, if insurers agree to lessen onerous access barriers for high-risk patients.

10 Mar 2018

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF76.10 +0.86
Pfizer Inc. (PFE.N) $36.85 +0.17
Bayer AG (BAYGn.DE) €97.34 -0.13
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €66.31 +0.44
Merck & Co., Inc. (MRK.N) $59.41 -0.22
Amgen, Inc. (AMGN.OQ) $175.37 +0.54
Roche Holding Ltd. (ROG.S) CHF218.10 +0.35
Roche Holding Ltd. (RO.S) CHF223.00 +0.40
Eli Lilly And Co (LLY.N) $82.55 +1.41

Earnings vs. Estimates